Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection
Vanessa Monteil, Matheus Dyczynski, Volker M. Lauschke, et al.
EMBO Molecular Medicine (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 105

Showing 1-25 of 105 citing articles:

Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19
Liam Gaziano, Claudia Giambartolomei, Alexandre C. Pereira, et al.
Nature Medicine (2021) Vol. 27, Iss. 4, pp. 668-676
Open Access | Times Cited: 194
COVID-19 therapeutics: Challenges and directions for the future
Philip C. Robinson, David Liew, Helen Tanner, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 15
Open Access | Times Cited: 144
Enzyme Therapy: Current Challenges and Future Perspectives
Miguel de la Fuente, Laura Lombardero, Alfonso Gómez-González, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 17, pp. 9181-9181
Open Access | Times Cited: 123
An overview on the treatments and prevention against COVID-19
Yunes Panahi, Armita Mahdavi Gorabi, Sona Talaei, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 51
Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets
Masoumeh Farahani, Zahra Niknam, Leila Mohammadi Amirabad, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 145, pp. 112420-112420
Open Access | Times Cited: 103
A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells
Elena Garreta, Patricia Prado, Megan L. Stanifer, et al.
Cell Metabolism (2022) Vol. 34, Iss. 6, pp. 857-873.e9
Open Access | Times Cited: 70
Clinical grade ACE2 as a universal agent to block SARS‐CoV ‐2 variants
Vanessa Monteil, Brett Eaton, Elena Postnikova, et al.
EMBO Molecular Medicine (2022) Vol. 14, Iss. 8
Open Access | Times Cited: 46
Improving Protein Quantity and Quality—The Next Level of Plant Molecular Farming
Hai Liu, Michael P. Timko
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1326-1326
Open Access | Times Cited: 45
Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development—Current State-of-the-Art and Future Perspectives
Sonia Youhanna, Aurino M. Kemas, Lena C. Preiss, et al.
Pharmacological Reviews (2022) Vol. 74, Iss. 1, pp. 141-206
Open Access | Times Cited: 39
Crimean–Congo haemorrhagic fever virus uses LDLR to bind and enter host cells
Vanessa Monteil, Shane C. Wright, Matheus Dyczynski, et al.
Nature Microbiology (2024) Vol. 9, Iss. 6, pp. 1499-1512
Open Access | Times Cited: 12
Lower Expression of SARS-CoV-2 Host Cell Entry Genes in the Intestinal Mucosa of IBD Patients With Quiescent or Mildly Active Disease
Laura Francesca Pisani, Guglielmo Albertini Petroni, Gabriela A. N. Crespi, et al.
Inflammatory Bowel Diseases (2025)
Closed Access | Times Cited: 1
Research Progress, Challenges, and Breakthroughs of Organoids as Disease Models
Yisheng Huang, Zhijie Huang, Zhengming Tang, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 56
Inhaled ACE2-engineered microfluidic microsphere for intratracheal neutralization of COVID-19 and calming of the cytokine storm
Zhen Wang, Lei Xiang, Feng Lin, et al.
Matter (2021) Vol. 5, Iss. 1, pp. 336-362
Open Access | Times Cited: 54
Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury
Murat Öz, Dietrich E. Lorke
Biomedicine & Pharmacotherapy (2021) Vol. 136, pp. 111193-111193
Open Access | Times Cited: 53
Quantifying Renin-Angiotensin-System Alterations in COVID-19
Fabrizio Pucci, Filippo Annoni, Robson A.S. Santos, et al.
Cells (2021) Vol. 10, Iss. 10, pp. 2755-2755
Open Access | Times Cited: 43
The interacting physiology of COVID‐19 and the renin‐angiotensin‐aldosterone system: Key agents for treatment
Eugenie R. Lumbers, Richard Head, Gary R. Smith, et al.
Pharmacology Research & Perspectives (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 36
Rapid Generation of Circulating and Mucosal Decoy Human ACE2 using mRNA Nanotherapeutics for the Potential Treatment of SARS‐CoV‐2
Jeonghwan Kim, Antony Jozić, Anindit Mukherjee, et al.
Advanced Science (2022) Vol. 9, Iss. 35
Open Access | Times Cited: 36
Force-tuned avidity of spike variant-ACE2 interactions viewed on the single-molecule level
Rong Zhu, Daniel Canena, Mateusz Sikora, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 33
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 32
3D printed human organoids: High throughput system for drug screening and testing in current COVID‐19 pandemic
Arpana Parihar, Vasundhara Pandita, Raju Khan
Biotechnology and Bioengineering (2022) Vol. 119, Iss. 10, pp. 2669-2688
Closed Access | Times Cited: 30
Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor
Tümay Capraz, Nikolaus F. Kienzl, Elisabeth Laurent, et al.
eLife (2021) Vol. 10
Open Access | Times Cited: 36
Cross-validation of SARS-CoV-2 responses in kidney organoids and clinical populations
Louisa Helms, Silvia Marchianò, Ian B. Stanaway, et al.
JCI Insight (2021) Vol. 6, Iss. 24
Open Access | Times Cited: 34
Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer
Robert H. Shoemaker, Reynold A. Panettieri, Steven K. Libutti, et al.
PLoS ONE (2022) Vol. 17, Iss. 7, pp. e0271066-e0271066
Open Access | Times Cited: 27
Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices
Tushar Saha, Miguel E. Quiñones‐Mateu, Shyamal C. Das
International Journal of Pharmaceutics (2022) Vol. 624, pp. 122042-122042
Open Access | Times Cited: 26
Page 1 - Next Page

Scroll to top